BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 12468342)

  • 1. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
    Leeper K; Garcia R; Swisher E; Goff B; Greer B; Paley P
    Gynecol Oncol; 2002 Oct; 87(1):52-6. PubMed ID: 12468342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
    Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
    Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
    Lu KH; Garber JE; Cramer DW; Welch WR; Niloff J; Schrag D; Berkowitz RS; Muto MG
    J Clin Oncol; 2000 Jul; 18(14):2728-32. PubMed ID: 10894872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.
    Colgan TJ; Murphy J; Cole DE; Narod S; Rosen B
    Am J Surg Pathol; 2001 Oct; 25(10):1283-9. PubMed ID: 11688463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
    Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
    Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
    Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
    Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.